Targeted drug delivery vehicles mediated by nanocarriers and aptamers for posterior eye disease therapeutics: barriers, recent advances and potential opportunities. (24th January 2022)

• Record Type: Journal Article
• Authors: Zhang, Tingting; Jin, Xin; Zhang, Nan; Jiao, Xinyi; Ma, Yuanyuan; Liu, Rui; Liu, Boshi; Li, Zheng
• Is Part Of: Nanotechnology. Volume 33:Number 16(2022)
• Publication Date: 2022-01-24
• Subjects: posterior segment eye diseases -- nanocarriers -- aptamer -- drug delivery system -- target; Nanotechnology -- Periodicals; Nanotechnology -- Periodicals; Nanotechnology; Publications périodiques; Nanotechnologies; Periodicals; 620.5
• DOI: 10.1088/1361-6528/ac46d5
• Languages: English
• ISSNs: 0957-4484

Abstract

Abstract: Nanomedicine and aptamer have excellent potential in giving play to passive and active targeting respectively, which are considered to be effective strategies in the retro-ocular drug delivery system. The presence of closely adjoined tissue structures in the eye makes it difficult to administer the drug in the posterior segment of the eye. The application of nanomedicine could represent a new avenue for the treatment, since it could improve penetration, achieve targeted release, and improve bioavailability. Additionally, a novel type of targeted molecule aptamer with identical objective was proposed. As an emerging molecule, aptamer shows the advantages of penetration, non-toxicity, and high biocompatibility, which make it suitable for ocular drug administration. The purpose of this paper is to summarize the recent studies on the effectiveness of nanoparticles as a drug delivery to the posterior segment of the eye. This paper also creatively looks forward to the possibility of the combined application of nanocarriers and aptamers as a new method of targeted drug delivery system in the field of post-ophthalmic therapy.